Zacks: Analysts Expect Clearside Biomedical, Inc. (NASDAQ:CLSD) Will Announce Quarterly Sales of $13.73 Million

Equities research analysts expect Clearside Biomedical, Inc. (NASDAQ:CLSD) to post sales of $13.73 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Clearside Biomedical’s earnings, with the lowest sales estimate coming in at $3.07 million and the highest estimate coming in at $24.00 million. Clearside Biomedical reported sales of $10,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 137,200%. The business is scheduled to report its next earnings report on Wednesday, March 9th.

According to Zacks, analysts expect that Clearside Biomedical will report full-year sales of $17.62 million for the current financial year, with estimates ranging from $6.96 million to $27.89 million. For the next fiscal year, analysts anticipate that the firm will report sales of $12.76 million, with estimates ranging from $4.00 million to $19.57 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Clearside Biomedical.

Clearside Biomedical (NASDAQ:CLSD) last released its earnings results on Wednesday, November 10th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Clearside Biomedical had a negative return on equity of 161.73% and a negative net margin of 652.60%. During the same period in the prior year, the business earned ($0.05) earnings per share.

Several research analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Clearside Biomedical in a report on Wednesday, September 22nd. Zacks Investment Research raised Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Monday, November 15th. Wedbush reaffirmed a “buy” rating and issued a $18.00 price target on shares of Clearside Biomedical in a report on Tuesday, September 21st. Finally, JMP Securities reaffirmed a “buy” rating and issued a $11.00 price target on shares of Clearside Biomedical in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $11.95.

Shares of NASDAQ CLSD traded up $0.28 during trading on Thursday, hitting $4.04. The company had a trading volume of 462,536 shares, compared to its average volume of 1,276,238. The company has a market cap of $241.05 million, a P/E ratio of -8.78 and a beta of 1.73. Clearside Biomedical has a 52 week low of $1.66 and a 52 week high of $7.73. The business’s 50-day moving average is $5.44 and its 200 day moving average is $4.99.

In other Clearside Biomedical news, major shareholder Bradford T. Whitmore sold 99,400 shares of the business’s stock in a transaction on Monday, August 30th. The shares were sold at an average price of $7.06, for a total transaction of $701,764.00. Following the sale, the insider now directly owns 3,529,845 shares of the company’s stock, valued at approximately $24,920,705.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 321,488 shares of company stock worth $2,227,836. Company insiders own 11.30% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in shares of Clearside Biomedical by 50.0% in the second quarter. JPMorgan Chase & Co. now owns 7,500 shares of the company’s stock worth $37,000 after acquiring an additional 2,500 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Clearside Biomedical in the first quarter worth $51,000. Walleye Capital LLC acquired a new position in shares of Clearside Biomedical in the second quarter worth $88,000. Squarepoint Ops LLC acquired a new position in shares of Clearside Biomedical in the first quarter worth $248,000. Finally, Ameritas Investment Company LLC acquired a new position in shares of Clearside Biomedical in the second quarter worth $247,000. 33.13% of the stock is currently owned by institutional investors and hedge funds.

About Clearside Biomedical

Clearside Biomedical, Inc is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H.

Read More: Why are analyst ratings important in trading stocks?

Get a free copy of the Zacks research report on Clearside Biomedical (CLSD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.